Towards a TDP-43-based biomarker for ALS and FTLD

Towards a TDP-43-based biomarker for ALS and FTLD

TDP-43 accumulates in nerve cells of nearly all cases of amyotrophic lateral sclerosis (ALS, the commonest form of motor neuron disease) and in the majority of Tau-negative frontotemporal lobar degeneration (FTLD). There is currently no biochemical test or marker of disease activity for ALS or FTLD...

Descripció completa

Dades bibliogràfiques
Autors principals:	Feneberg, E, Gray, E, Ansorge, O, Talbot, K, Turner, M
Format:	Journal article
Publicat:	Springer US 2018

Ítems similars

Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP
per: Feneberg, E, et al.
Publicat: (2021)

Evidence of cerebellar TDP-43 loss of function in FTLD-TDP
per: Sarah Pickles, et al.
Publicat: (2022-07-01)

The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD
per: Britt A. Berning, et al.
Publicat: (2019-04-01)

FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansion.
per: Bäumer, D, et al.
Publicat: (2014)

TDP-43 based biomarker development in amyotrophic lateral sclerosis
per: Feneberg, E
Publicat: (2019)

NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility
per: Amanda M. Gleixner, et al.
Publicat: (2022-06-01)

Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors
per: Luigi Fiondella, et al.
Publicat: (2023-04-01)

Codon-optimized TDP-43 mediates neurodegeneration in a Drosophila model of ALS/FTLD
per: Tanzeen Yusuff, et al.
Publicat: (2023-03-01)

Amyotrophic lateral sclerosis with a heterozygous D91A SOD1 variant and classical ALS-TDP neuropathology
per: Feneberg, E, et al.
Publicat: (2020)

C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation
per: Keith A. Josephs, et al.
Publicat: (2019-07-01)

mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms.
per: Barbara Scherz, et al.
Publicat: (2018-01-01)

Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies
per: Shunsuke Koga, et al.
Publicat: (2023-07-01)

TDP-43 Proteinopathy Specific Biomarker Development
per: Isabell Cordts, et al.
Publicat: (2023-02-01)

Publisher Correction to: Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies
per: Shunsuke Koga, et al.
Publicat: (2023-07-01)

TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy
per: Turner, B, et al.
Publicat: (2008)

An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress
per: Feneberg, E, et al.
Publicat: (2020)

Regional and hemispheric susceptibility of the temporal lobe to FTLD-TDP type C pathology
per: V. Borghesani, et al.
Publicat: (2020-01-01)

An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress
per: Emily Feneberg, et al.
Publicat: (2020-10-01)

Aberrant TDP‐43 phosphorylation: a key wind gap from TDP‐43 to TDP‐43 proteinopathy
per: Zi‐Qi Huang, et al.
Publicat: (2021-06-01)

TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy
per: Lumi Zhang, et al.
Publicat: (2020-01-01)

ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation.
per: Adam K Walker, et al.
Publicat: (2013-01-01)

The role of mitochondrial dysfunction and ER stress in TDP-43 and C9ORF72 ALS
per: Dafinca, R, et al.
Publicat: (2021)

Advancements in TDP-43 research: Towards biomarkers and therapeutic targets for amyotrophic lateral sclerosis
per: Yuhan Wu, et al.
Publicat: (2025-03-01)

TDP-43 as a potential retinal biomarker for neurodegenerative diseases
per: Margit Glashutter, et al.
Publicat: (2025-02-01)

Low T-cell reactivity to TDP-43 peptides in ALS
per: Swetha Ramachandran, et al.
Publicat: (2023-07-01)

CK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation
per: Vivian I. Ko, et al.
Publicat: (2024-06-01)

Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models.
per: Nirma D Perera, et al.
Publicat: (2014-01-01)

Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models.
per: Nirma D Perera, et al.
Publicat: (2014-01-01)

Restoring functional TDP-43 oligomers in ALS and laminopathic cellular models through baicalein-induced reconfiguration of TDP-43 aggregates
per: Hsiang-Yu Chang, et al.
Publicat: (2024-02-01)

TDP-43 mislocalization drives neurofilament changes in a novel model of TDP-43 proteinopathy
per: Rachel Atkinson, et al.
Publicat: (2021-02-01)

LIPIDS ALTERATION IN TDP-43
per: Irene García Toledo, et al.
Publicat: (2023-10-01)

The cooperative binding of TDP-43 to GU-rich RNA repeats antagonizes TDP-43 aggregation
per: Juan Carlos Rengifo-Gonzalez, et al.
Publicat: (2021-09-01)

TDP-43: From Alzheimer’s Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy
per: Wendi Huang, et al.
Publicat: (2020-02-01)

The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43.
per: Ya-Fei Xu, et al.
Publicat: (2013-01-01)

In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use
per: Juan I. López-Carbonero, et al.
Publicat: (2024-06-01)

Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology
per: Kyota Fujita, et al.
Publicat: (2018-01-01)

Disease-modifying effects of metabolic perturbations in ALS/FTLD
per: Ali Jawaid, et al.
Publicat: (2018-12-01)

RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy
per: Julie C Necarsulmer, et al.
Publicat: (2023-10-01)

A C-Terminally Truncated TDP-43 Splice Isoform Exhibits Neuronal Specific Cytoplasmic Aggregation and Contributes to TDP-43 Pathology in ALS
per: Marc Shenouda, et al.
Publicat: (2022-06-01)

TDP-43 Cytoplasmic Translocation in the Skin Fibroblasts of ALS Patients
per: Miguel A. Rubio, et al.
Publicat: (2022-01-01)